CN Mobile Logo

Search form


Prostate Cancer

Active Surveillance for Prostate Cancer: How to Do It Right

In this review of active surveillance for favorable-risk prostate cancer, we will discuss the rationality of this approach, the biological evidence for employing active surveillance in Gleason pattern 3 and 4 prostate cancer, patient selection for active surveillance, clinical trial data on active surveillance, and the role of prostate cancer biomarkers and imaging studies for clinical decision making in patients with low-risk disease.

Prostate Cancer

In this article, we look at both metastatic hormone-sensitive and metastatic castration-resistant disease, and we highlight several of the emerging categories of advanced prostate cancer that have direct implications for patient management.

Germline genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will test positive for pathogenic gene variants.

A new study found that patients with mCRPC had higher PSA response with enzalutamide vs abiraterone, but no difference in time to progression, and reported worse outcomes in those with quantifiable ctDNA.

Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.

Continued enzalutamide with abiraterone failed to improve PFS in men with metastatic castration-resistant prostate cancer who progressed on enzalutamide alone.

A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.

Androgen deprivation therapy can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to results of a phase III trial.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.